Archives
- 2026-07
- 2026-06
- 2026-05
- 2026-04
- 2026-03
- 2026-02
- 2026-01
- 2025-12
- 2025-11
- 2025-10
- 2025-09
- 2025-03
- 2025-02
- 2025-01
- 2024-12
- 2024-11
- 2024-10
- 2024-09
- 2024-08
- 2024-07
- 2024-06
- 2024-05
- 2024-04
- 2024-03
- 2024-02
- 2024-01
- 2023-12
- 2023-11
- 2023-10
- 2023-09
- 2023-08
- 2023-07
- 2023-06
- 2023-05
- 2023-04
- 2023-03
- 2023-02
- 2023-01
- 2022-12
- 2022-11
- 2022-10
- 2022-09
- 2022-08
- 2022-07
- 2022-06
- 2022-05
- 2022-04
- 2022-03
- 2022-02
- 2022-01
- 2021-12
- 2021-11
- 2021-10
- 2021-09
- 2021-08
- 2021-07
- 2021-06
- 2021-05
- 2021-04
- 2021-03
- 2021-02
- 2021-01
- 2020-12
- 2020-11
- 2020-10
- 2020-09
- 2020-08
- 2020-07
- 2020-06
- 2020-05
- 2020-04
- 2020-03
- 2020-02
- 2020-01
- 2019-12
- 2019-11
- 2019-10
- 2019-09
- 2019-08
- 2019-07
- 2019-06
- 2019-05
- 2019-04
- 2018-07
-
br Conclusion and prospect Small GTPases are very
2022-01-10

5. Conclusion and prospect Small GTPases are very important regulatory proteins of eukaryotes. They play crucial regulatory function in various movement processes of organism [75], [76], [77]. Different nanoparticles used to investigate the interaction with small GTPases inside Palbociclib have b
-
The experiments reported herein were designed to test whethe
2022-01-10

The experiments reported herein were designed to test whether co-expression of MRP and GSTP1-1 offers a level of protection from certain cytotoxic drugs not achieved by the expression of either protein alone. This was accomplished by stable transfection with expression vectors into MCF7/WT cells, w
-
br Conflict of interest statement br
2022-01-10

Conflict of interest statement Acknowledgements RF is supported by Pancreatic Cancer Research Fund (grant to MF); MF is supported by Prostate Cancer UK (PG12-23 and PG13-029). Background Lysophosphatidylinositol Molecular species and the biosynthesis of phosphatidylinositol, the precu
-
Firstly the impact on activity
2022-01-10

Firstly, the impact on activity and selectivity was made by replacing the 2, 3-di-F substitution of ring A with 2,3-OCHO- () and 2-NO () substitutions, and replacing the 3, 5-di-F substitution of ring B with 3,5-di-OMe () and 3,5-di-Me () substitutions. Compound kept moderate activity (EC = 220 nM)
-
Raltitrexed br Methods GLUT DS was diagnosed either when ana
2022-01-07

Methods GLUT1DS was diagnosed either when analysis of the SLC2A1 gene showed a pathogenic mutation and/or when cerebrospinal fluid (CSF) analysis met the criteria for GLUT1DS: a CSF Raltitrexed below the 10th percentile, a cerebrospinal fluid (CSF) to blood ratio below the 25th percentile and CS
-
Genetic disruption or pharmacologic inhibition
2022-01-07

Genetic disruption or pharmacologic inhibition of the hepatic glucagon pathway has invariably been shown to increase pancreatic α cell mass. This has been observed in glucagon receptor (GCGR) knockout (Gcgr−/−) mice (Gelling et al., 2003), glucagon knockout mice (Hayashi et al., 2009), prohormone co
-
The regulation of the stem cell compartment in CML is
2022-01-07

The regulation of the stem cell compartment in CML is dynamic, in particular, during disease progression to a blast crisis and might involve a complex cross-regulation of Hh, Wnt, Notch, and hox signaling pathways (). Significant upregulation of Ptch1 and cyclin D1, upon other proteins, marks the bl
-
Ro 48-8071 receptor Discrepancies in the reported results an
2022-01-07

Discrepancies in the reported results and conclusions from different groups regarding studies in ghrelin−/− and ghsr−/− mice are likely explained by the mixed background of the mutant mice used in the different studies [35]; although in the case of mice exposed to HFD, exposure to a HFD immediately
-
br Therapeutic approaches exploiting Cx function
2022-01-07

Therapeutic approaches exploiting Cx43 function Due to their potential role in cancer metastasis, attempts have been made to alter connexin function to inhibit cancer growth. Therapeutic approaches include Cx43 peptide mimetics, Cx43 inhibitors, chemical agents capable of enhancing Cx43 function,
-
br Acknowledgments This research was supported in
2022-01-07

Acknowledgments This research was supported in part by National Institutes of Health IDeA Program COBRE grant GM110732; a USDA National Institute of Food and Agriculture Hatch project; and the Montana State University Agricultural Experiment Station. Introduction Propofol (2,6-Diisopropylphen
-
Thrilled by these promising results our quest for
2022-01-07

Thrilled by these promising results, our quest for discovering new PPAR-γ/FFAR1 co-agonists was directed towards exploring the other two new scaffolds. So, in this proposed manuscript, we will describe our efforts regarding the synthesis, biological evaluation and molecular docking studies of the be
-
The inhibitory activities of the
2022-01-07

The inhibitory activities of the compounds with the modification of the amino group against human liver FBPase are summarized in . Replacement of the amino group of with hydrophobic substituent such as a methyl group () led to a substantial loss of activity (IC=995nM). Similarly, replacement with h
-
The Rho family of GTPases is composed
2022-01-07

The Rho family of GTPases is composed of many small ubiquitous signaling G proteins that bind to guanosine triphosphate (GTP) and hydrolyze it to guanosine diphosphate (GDP). They act as switches: when binding to GTP, they are active and associate with a variety of target proteins that regulate intr
-
Signaling pathways such as BMP FGF
2022-01-07

Signaling pathways such as BMP, FGF, and WNT are strongly involved in the process of endochondral ossification and Meckel's cartilage development [20]. Interestingly, absence of BMP antagonist, Noggin, in Meckel's cartilage, resulted in a phenotype, very similar to that of Setdb1 CKO [16]. To examin
-
Anti apoptotic Bcl proteins have become attractive
2022-01-07

Anti-apoptotic Bcl-2 proteins have become attractive targets for anti-cancer agents development, because they are associated with progression of a wide variety of human cancers., , The small-molecular Bcl-2 inhibitor venetoclax (ABT-199) () has been approved recently for the treatment of patients w
16225 records 553/1082 page Previous Next First page 上5页 551552553554555 下5页 Last page